Clark Capital Management Group Inc. purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 178,847 shares of the medical instruments supplier's stock, valued at approximately $40,967,000. Clark Capital Management Group Inc. owned 0.06% of Becton, Dickinson and Company as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Becton, Dickinson and Company by 50.6% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock worth $18,808,000 after purchasing an additional 27,581 shares in the last quarter. FORA Capital LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $3,458,000. Foster Victor Wealth Advisors LLC bought a new position in Becton, Dickinson and Company in the 1st quarter worth approximately $6,406,000. Finally, GAMMA Investing LLC increased its position in shares of Becton, Dickinson and Company by 29.9% during the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after purchasing an additional 748 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Becton, Dickinson and Company
In other news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Claire Fraser sold 863 shares of Becton, Dickinson and Company stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $192.30, for a total transaction of $165,954.90. Following the completion of the sale, the director owned 23,143 shares in the company, valued at approximately $4,450,398.90. This trade represents a 3.59% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on BDX shares. Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their price target for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Piper Sandler reaffirmed a "neutral" rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Barclays dropped their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Four analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $211.44.
Check Out Our Latest Analysis on BDX
Becton, Dickinson and Company Stock Down 1.3%
Shares of BDX stock traded down $2.41 during trading hours on Wednesday, hitting $188.08. 519,959 shares of the company's stock traded hands, compared to its average volume of 2,583,560. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The stock has a market cap of $53.91 billion, a price-to-earnings ratio of 33.81, a PEG ratio of 1.43 and a beta of 0.27. The stock's fifty day simple moving average is $185.72 and its two-hundred day simple moving average is $192.33. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm's revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
